Discovery

Development

Testing

Clinical Manufacture

Commercial Manufacture

Drug Product Fill & Finish

Antibody Drug Conjugates

Technologies & Platforms

WuXi Biologics Receives Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC

SHANGHAI, Mar. 30, 2017 — WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec Affiliate, today announced that it had received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm.

Asia-Pacific Bioprocessing Excellence Awards aims to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and best practices in manufacturing, WuXi Biologics has been recognized for its outstanding performance that facilitating biomanufacturing excellence at enhanced speed, reduced cost and superior quality.

As an open-access biologics technology platform, WuXi Biologics opened its state-of-the-art biologics manufacturing facilities at Wuxi city in 2012, which is the first in China that met cGMP standards of the United States, the European Union, and China. In 2015, WuXi began construction of world’s largest mammalian cell culture manufacturing facility using disposable bioreactors with a planned manufacturing capacity of 30000L, and completed construction of Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors in 2016, offering end-to-end solution to our worldwide customers and partners.

“WuXi Biologics is honored to be recognized by IMAPAC,” said Dr. Chris Chen, CEO of WuXi Biologics, “The award truly reflects all of the efforts we have put forth to provide our customers with high-quality and best-in-class service to help accelerate biologics development from concept to commercialization.”

About WuXi Biologics

WuXi Biologics, a WuXi AppTec Affiliate, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi’s Biologics services, please visit:http://www.wuxibiologics.com.

Media Contacts:

Jia Li, WuXi Biologics
+86-21-2066-4528
li_jia0102@wuxiapptec.com

BACK